Tags: Johnson | J&J | Stake | Elan

Johnson & Johnson Sells Entire Stake in Elan

Thursday, 13 Jun 2013 06:56 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Johnson & Johnson sold 25.4 million shares of Elan Corp., ending a relationship started four years ago to develop the Alzheimer's disease drug bapineuzumab.

J&J, based in New Brunswick, New Jersey, bought an 18 percent stake in the Irish biotechnology company for $1 billion in 2009 and took over bapineuzumab's development. The medicine, designed to slow Alzheimer's by reducing amyloid plaque buildup, failed last year in the final stage of testing.

J&J sold 82 million shares back to Elan on April 18, the maximum allowed, as part of a Dutch auction, said Ernie Knewitz, a company spokesman. It sold the remaining American depositary receipts Thursday for $332.5 million, carrying out J&J's plans to divest its Elan holdings following a portfolio review, Knewitz said. Each receipt is equal to an ordinary Elan share.

The sale wasn't related to Royalty Pharma's $6.7 billion bid to take over Elan, Knewitz said in a telephone interview. Royalty Pharma, which invests in royalty streams from medicines, said Thursday it may be forced to end its bid for Elan if investors approve a share-repurchasing program or any of three other proposals by the Dublin-based company’s board.

J&J's sale isn't material for Elan, because it’s only 5 percent of the company and won't affect the 50 percent required to approve a transaction, Michael Yee, an analyst at RBC Capital Markets in San Francisco, said in an e-mail.

J&J, the world's largest seller of health-care products, was developing bapineuzumab with New York-based Pfizer Inc. Eli Lilly & Co. said Thursday it stopped a mid-stage trial of another Alzheimer’s disease drug, known as a BACE inhibitor, after signs of potential liver problems.

© Copyright 2014 Bloomberg News. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web

Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
You May Also Like
Around the Web

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved